Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports.
Primary breast lymphoma (PBL) is a rare form of extranodal non-Hodgkin's lymphoma (NHL), whose own specific biological characteristics still need to be fully defined. No significant prognostic factor has been found and the optimal therapeutic strategy is uncertain. However, an intensified systemic therapy has been advocated to prevent relapse, even in patients who show a complete response to local treatment. We report two cases of primary diffuse large B-cell breast lymphoma, review the literature about this topic, and discuss treatment options. We conclude that differential therapeutic strategies based on the risk of relapse associated with the International Prognostic Index (IPI) are a reasonable way to approach PBL, and can avoid undue toxicity deriving from treatment.
Stasi
Roberto
R
Department of Medical Sciences, Regina Apostolorum Hospital, Via S. Francesco, Albano Laziale 5000041, Italy. roberto.stasi@uniroma2.it
Evangelista
Maria Laura
ML
Brunetti
Maurizio
M
Bussa
Stefano
S
Maritati
Raffaele
R
Turrini
Luca
L
Taccogna
Silvia
S
Crescenzi
Anna
A
Angelini
Francesco
F
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D001940:Breast / Q000737:chemistry / Q000473:pathology / Q000503:physiopathology; D001943:Breast Neoplasms / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007278:Injections, Spinal; D007770:L-Lactate Dehydrogenase / Q000097:blood; D002955:Leucovorin / Q000627:therapeutic use; D017493:Leukocyte Common Antigens; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D015412:Mastectomy, Segmental; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000964:Antimetabolites, Antineoplastic; D001761:Bleomycin; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D017493:Leukocyte Common Antigens; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate